Therapeutic properties of biological response modifiers. A discussion of preclinical and clinical studies.
Talmadge
J E
JE
Smith Kline and French Laboratories, Department of Immunology, King of Prussia, Pa.
D001685:Biological Factors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003115:Colony-Stimulating Factors / Q000494:pharmacology / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007167:Immunotherapy; D007262:Infusions, Intravenous; D007371:Interferon-gamma / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D007376:Interleukin-2 / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D009369:Neoplasms / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage / Q000627:therapeutic use
D001685:Biological Factors; D003115:Colony-Stimulating Factors; D007376:Interleukin-2; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma